Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates

Clinica Terapeutica

Volumn 166, Issue 6, 2015, Pages 74-380

  Li, Z X ^a   Liu, Youning ^b   Wang, R ^b   Li, A M ^b  

^a Second Artillery General Hospital   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Gram negative clinical isolates; Gram positive clinical isolates; MIC; Nemonoxacin

Indexed keywords

AZITHROMYCIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; NEMONOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIC50; MIC90; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; COMPARATIVE STUDY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; QUINOLONES;

EID: 84991735224     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: 10.7417/T.2015.1903     Document Type: Article

References (13)

1. Poole RM. Nemonoxacin: first global approval.Drugs. 2014;74:1445-53.
2. Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.Antimicrob Agents Chemother. 2014;58:1800-1.
3. Chen YH, Liu CY, Ko WC, et al. Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010.Eur J Clin Microbiol Infect Dis. 2014;33:233-9.
4. Roychoudhury S, Ledoussal B.Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant Gram-positive pathogens. Curr Drug Targets Infect Disord 2002;2:51-65.
5. Lai CC,Tan CK,Lin SH,Liao CH, et al. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother 2009;64:73-8.
6. Tan CK,Lai CC,Liao CH, et al. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2009;64: 428-9.
7. Adam HJ, Laing NM,King CR, et al. In vitro activity of Nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 2009;53:4915-20.
8. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010;54:1338-42.
9. Aktas Z, Gonullu N, Salcioglu M, et al. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin. Int J Antimicrob Agents 2002;20 :196.
10. Tran TT, Munita JM, Arias CA. Mechanisms of drug resistance: daptomycin resistance. Ann N Y Acad Sci. 2015 Oct 23. doi: 10.1111/nyas.12948.
11. Liapikou A, Cillóniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015 18; 9:4565-72.
12. Ghamrawi RJ, Neuner E, Rehm SJ. Ceftaroline fosamil: A super-cephalosporin? Cleve Clin J Med. 2015; 82(7):437-44.
13. Johnson PC, Vaduganathan M, Phillips KM, O'Donnell WJ. A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitis. Proc (Bayl Univ Med Cent). 2015; 28(4):466-8.